Form 4: 89bio Director Martin Babler Acquires Stock Options
SEC Form 4 Filing
Director Martin Babler acquired stock options for 67,700 shares of 89bio, Inc. common stock on May 2, 2024.
Summary
- On May 2, 2024, Martin Babler, a director of 89bio, Inc., acquired stock options for 67,700 shares of the company's common stock.
- The exercise price of these options is $8.86 per share.
- The options vest in equal installments on April 13, 2025, April 13, 2026, and April 13, 2027, contingent upon continued service to the issuer.
- The options expire on May 2, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director. The acquisition of options could be seen as a slightly positive sign, indicating confidence, but it's not a strong signal.
Positives
- The acquisition of stock options by a director may signal confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency regarding the holdings and transactions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/02/2024 | Date of transaction: Martin Babler acquired stock options. |
| 05/02/2034 | Expiration date of the stock options. |
| 04/13/2025 | First vesting date for the stock options. |
| 04/13/2026 | Second vesting date for the stock options. |
| 04/13/2027 | Third vesting date for the stock options. |
| 05/03/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.